Monitoring the transition of patients on biologics in rheumatoid arthritis: Consensus guidance for pharmacists

Monitoring the transition of patients on biologics in rheumatoid arthritis: Consensus guidance for pharmacists

Background: Recent approvals for novel agents such as the small molecule Janus kinase inhibitors (JAKi), combined with the advent of biosimilars has widened the gamut of available therapeutic options in the treatment of rheumatoid arthritis (RA). This combined with the introduction of mandatory non-...

Full description

Bibliographic Details
Main Authors: Bardi, M. (Author), Chan, J. (Author), Choquette, D. (Author), Sihota, A. (Author), Smith, B.K (Author), Torani, G. (Author), Whiskin, C. (Author)
Format: Article
Language:English
Published: Grupo de Investigacion en Atencion Farmaceutica 2021
Subjects:
adalimumab
algorithm
Algorithms
Antirheumatic Agents
Arthritis, Rheumatoid
Article
biosimilar agent
Biosimilar Pharmaceuticals
Canada
certolizumab pegol
clinical competence
Clinical Competence
clinical decision making
consensus
Consensus
decision making
disease activity
drug safety
Drug Substitution
etanercept
expectation
fatigue
fecal microbiota transplantation
follow up
group process
Group Processes
human
immune response
inflammatory bowel disease
Janus kinase inhibitor
Janus Kinase Inhibitors
medical education
nocebo effect
Nocebo Effect
pharmacist
Pharmacists
quality of life
rheumatoid arthritis
rheumatologist
Rheumatologists
tocilizumab
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items